Neumora Therapeutics (NASDAQ:NMRA) Sets New 1-Year High – Here’s What Happened

Neumora Therapeutics, Inc. (NASDAQ:NMRA) shares hit a new 52-week high during trading on Thursday . The stock traded as high as $3.47 and last traded at $3.3350, with a volume of 1859404 shares trading hands. The stock had previously closed at $3.00.

Wall Street Analyst Weigh In

Several research analysts have issued reports on NMRA shares. Stifel Nicolaus increased their price target on Neumora Therapeutics from $2.00 to $3.00 and gave the stock a “hold” rating in a report on Monday, November 17th. Mizuho set a $6.00 target price on Neumora Therapeutics in a research report on Monday, January 5th. Leerink Partners began coverage on Neumora Therapeutics in a report on Monday, January 12th. They issued an “outperform” rating and a $8.00 target price on the stock. Royal Bank Of Canada raised shares of Neumora Therapeutics from a “sector perform” rating to an “outperform” rating and lifted their price target for the company from $4.00 to $7.00 in a research report on Monday, December 1st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Neumora Therapeutics in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, two have issued a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, Neumora Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $8.13.

Neumora Therapeutics Price Performance

The company has a current ratio of 6.85, a quick ratio of 6.85 and a debt-to-equity ratio of 0.15. The business has a 50-day moving average of $2.03 and a 200 day moving average of $2.01. The firm has a market capitalization of $546.38 million, a PE ratio of -2.22 and a beta of 3.20.

Institutional Investors Weigh In On Neumora Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. AlphaCore Capital LLC purchased a new stake in shares of Neumora Therapeutics during the second quarter valued at approximately $248,000. Catalyst Funds Management Pty Ltd bought a new position in Neumora Therapeutics in the 2nd quarter valued at $29,000. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Neumora Therapeutics in the 2nd quarter valued at $41,000. Savant Capital LLC purchased a new stake in shares of Neumora Therapeutics during the 2nd quarter valued at $52,000. Finally, Y Intercept Hong Kong Ltd bought a new stake in shares of Neumora Therapeutics during the 2nd quarter worth $42,000. 47.65% of the stock is owned by institutional investors.

About Neumora Therapeutics

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.